{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:39Z","timestamp":1791245199888,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunoglobulin replacement and prophylactic antibiotics are commonly used to prevent infections in patients with secondary hypogammaglobulinemia due to hematological malignancies but have never been directly compared. In this randomized controlled feasibility trial conducted in 7 hospitals in Australia and New Zealand, we enrolled patients with secondary hypogammaglobulinemia with either a history of recurrent\/severe infection or an immunoglobulin G level\u00a0&amp;lt;4 g\/L. Participants were randomized in a 1:2 ratio to immunoglobulin (0.4 g\/kg per 4\u00a0weeks IV) or daily antibiotics (trimethoprim-sulfamethoxazole 160\u00a0mg\/800\u00a0mg or, if contraindicated, 100\u00a0mg doxycycline) for 12\u00a0months. Participants allocated to antibiotics were allowed to crossover after grade \u22653 infections. The primary outcome was proportion of patients alive on the assigned treatment 12\u00a0months after randomization. Between August 2017 and April 2019, 63 patients were randomized: 42 to antibiotics and 21 to immunoglobulin. Proportion of participants alive on allocated treatment at 12\u00a0months was 76% in the immunoglobulin and 71% in the antibiotic arm (Fisher exact test P=.77; odds ratio, 0.78; 95%\u00a0CI, 0.22-2.52). The lower quartile for time to first major infection (median, not reached) was 11.1\u00a0months for the immunoglobulin and 9.7\u00a0months for the antibiotic arm (log-rank test, P=.65). Three participants in the immunoglobulin and 2 in the antibiotic arm had grade \u22653 treatment-related adverse events. A similar proportion of participants remained on antibiotic prophylaxis at 12\u00a0months to those on immunoglobulin, with similar rates of major infections. Our findings support the feasibility of progressing to a phase 3 trial. Trial registration #ACTRN12616001723471.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011231","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T14:05:58Z","timestamp":1712325958000},"page":"1787-1795","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-7185","authenticated-orcid":false,"given":"Zoe K.","family":"McQuilten","sequence":"first","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"2Department of Haematology, Monash Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3645-7988","authenticated-orcid":false,"given":"Robert","family":"Weinkove","sequence":"additional","affiliation":[{"name":"3Te Rerenga Ora Wellington Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast & Hutt Valley, Wellington, New Zealand"},{"name":"4Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand"},{"name":"5Department of Pathology & Molecular Medicine, University of Otago Wellington, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9661-6835","authenticated-orcid":false,"given":"Le Thi Phuong","family":"Thao","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4971","authenticated-orcid":false,"given":"Philip","family":"Crispin","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Canberra Hospital, Canberra, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Degelia","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dendle","sequence":"additional","affiliation":[{"name":"7Monash Infectious Diseases, Monash Health, Melbourne, Australia"},{"name":"8School of Clinical Sciences, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gilbertson","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Monash Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-5203","authenticated-orcid":false,"given":"Anna","family":"Johnston","sequence":"additional","affiliation":[{"name":"9Department of Haematology, Royal Hobart Hospital, Hobart, Australia"},{"name":"10Department of Medicine, University of Tasmania, Hobart, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastazia","family":"Keegan","sequence":"additional","affiliation":[{"name":"11PathWest Laboratory Medicine, King Edward Memorial Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5952-6395","authenticated-orcid":false,"given":"Dominic","family":"Pepperell","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Fiona Stanley Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humphrey","family":"Pullon","sequence":"additional","affiliation":[{"name":"13Department of Haematology, Waikato Hospital, Hamilton, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-8625","authenticated-orcid":false,"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"14Central Clinical School, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"van Tonder","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"15Department of Haematology, Concord Repatriation General Hospital, Sydney, Australia"},{"name":"16Concord Clinical School, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-1827","authenticated-orcid":false,"given":"Neil","family":"Waters","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5394","authenticated-orcid":false,"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Weston","sequence":"additional","affiliation":[{"name":"17Department of Haematology, Sunshine Coast University Hospital, Sunshine Coast, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-9575","authenticated-orcid":false,"given":"C. Orla","family":"Morrissey","sequence":"additional","affiliation":[{"name":"14Central Clinical School, Monash University, Melbourne, Australia"},{"name":"18Department of Infectious Diseases, Alfred Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-2340","authenticated-orcid":false,"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[{"name":"1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"2Department of Haematology, Monash Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"7","key":"2024040915302258200_bib1","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.3324\/haematol.2018.196543","article-title":"Immune failure, infection and survival in chronic lymphocytic leukemia","volume":"103","author":"Crassini","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2024040915302258200_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.15146","article-title":"Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in chronic lymphocytic leukaemia","volume":"181","author":"Crassini","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2024040915302258200_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"2024040915302258200_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"key":"2024040915302258200_bib5","unstructured":"UK DoH\n          . NHS England updated commissioning criteria for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England. 2019. Accessed 10 October 2023. http:\/\/igd.mdsas.com\/wp-content\/uploads\/Ig-PWG-Guidance-for-the-use-of-Ig-V1.3-12022019.pdf."},{"issue":"12","key":"2024040915302258200_bib6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024040915302258200_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.13374","article-title":"Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: systematic review and meta-analysis","volume":"104","author":"Mohyuddin","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"2024040915302258200_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/imj.14082","article-title":"Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey","volume":"49","author":"Wong","year":"2019","journal-title":"Intern Med J"},{"issue":"4","key":"2024040915302258200_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00277-013-1698-0","article-title":"Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"92","author":"Neumann","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"2024040915302258200_bib10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/tid.12298","article-title":"Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period","volume":"16","author":"Macesic","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"2024040915302258200_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"2024040915302258200_bib12","author":"Fagerland","year":"2017"},{"key":"2024040915302258200_bib13","author":"Fayers","year":"2001"},{"issue":"8905","key":"2024040915302258200_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"2","key":"2024040915302258200_bib15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood"},{"issue":"2","key":"2024040915302258200_bib16","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"issue":"14","key":"2024040915302258200_bib17","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia, intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Gale","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"2024040915302258200_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"key":"2024040915302258200_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40164-018-0110-0","article-title":"A\u00a0randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma","volume":"7","author":"Gregersen","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2024040915302258200_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-021-00490-8","article-title":"Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial","volume":"11","author":"Puig","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"2024040915302258200_bib21","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2024040915302258200_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jha2.683","article-title":"Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies","volume":"4","author":"Shields","year":"2023","journal-title":"EJHaem"},{"issue":"10325","key":"2024040915302258200_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"2024040915302258200_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/ACI.0000000000000696","article-title":"Global immunoglobulin supply: steaming towards the iceberg?","volume":"20","author":"Prevot","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2024040915302258200_bib25","article-title":"Immunoglobulin for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation","author":"Wyndham","year":"2019","journal-title":"MSAC Assessment Report"},{"key":"2024040915302258200_bib26","unstructured":"National Blood Authority\n          . What blood products are supplied-National product price list. Accessed 19 May 2023. https:\/\/www.blood.gov.au\/national-product-price-list."},{"issue":"2","key":"2024040915302258200_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000528959","article-title":"Challenges for plasma-derived medicinal products","volume":"50","author":"Strengers","year":"2023","journal-title":"Transfus Med Hemother"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1787\/2220835\/blooda_adv-2023-011231-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1787\/2220835\/blooda_adv-2023-011231-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T15:30:58Z","timestamp":1712676658000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/7\/1787\/498715\/Immunoglobulin-replacement-vs-prophylactic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011231","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}